Testofen

Natural health product licensed in Canada

Other names

Fenugreek, Fenugreek extract

Licence holder

Bioclinic Naturals Inc.

NPN or DIN-HM

80079448

Status

Active licence

Licence date

15 August 2017

Revision date

Not provided

Form

Capsule

Route of administration

Orale

Application type

Non traditionnelle

If this product were sold in France

• Conditions légales

  Trigonella foenum-graecum L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes.

  arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Non-medicinal ingredients

Cellulose microcristalline, Stéarate de magnésium, NA, Eau purifiée, Silice

Recommended doses in Canada

Uses authorised in Canada

Helps support testosterone production in men. Helps support normal levels of free testosterone in men. Helps support libido (sexual desire/drive/urge) in men. Helps support sexual arousal in healthy women.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

• Précautions et mises en garde

  Consult a health care practitioner if symptoms persist. Consult a health care practitioner if symptoms worsen. Consult a health care practitioner prior to use if you are pregnant. Consult a health care practitioner prior to use if you have diabetes. Consult a health care practitioner prior to use if you are attempting to conceive. Discontinue use if you experience joint pain or hot flashes. Consult a health care practitioner if you have benign prostate hypertrophy and/or prostate cancer. Consult your health care practitioner prior to use if you have a liver disease or disorder. Discontinue use and consult a health care practitioner if you experience breast pain, discomfort and/or tenderness. Do not use if you currently have or previously had breast cancer and/or breast tumours or if you have a predisposition to breast cancer, as indicated by an abnormal mammogram and/or biopsy, or a family member with breast cancer. Consult your health care practitioner prior to use if you are taking hormone replacement therapies or birth control pills. Ensure you are up-to-date on mammograms and gynaecological evaluations prior to use and during continued use. Discontinue use and consult a health care practitioner if you experience irregular menstruation (e.g. absence, recurrence, increased flow, spotting). Consult a health care practitioner prior to use if you have a history of hormonal or gynaecological disease, including endometriosis and/or uterine fibroids. Consult a health care practitioner prior to use if you have been diagnosed with hypoactive sexual disorder, sexual dysfunction or erectile dysfunction. Consult a health care practitioner prior to use if you suffer from any psychological disorder and/or condition such as frequent anxiety or depression. Keep out of reach of children. Adult women: Consult a health care practitioner if you experience abnormal hair growth.

Source

Official Health Canada record, licence 80079448

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.